[go: up one dir, main page]

EP3833348A4 - TRANSGLUTAMINASE 2 (TG2) INHIBITORS - Google Patents

TRANSGLUTAMINASE 2 (TG2) INHIBITORS Download PDF

Info

Publication number
EP3833348A4
EP3833348A4 EP19846381.2A EP19846381A EP3833348A4 EP 3833348 A4 EP3833348 A4 EP 3833348A4 EP 19846381 A EP19846381 A EP 19846381A EP 3833348 A4 EP3833348 A4 EP 3833348A4
Authority
EP
European Patent Office
Prior art keywords
transglutaminase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19846381.2A
Other languages
German (de)
French (fr)
Other versions
EP3833348A1 (en
EP3833348B1 (en
Inventor
David Campbell
Justin Chapman
Mui H. CHEUNG
Thoams R. DIRAIMONDO
Sergio G. Duron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sitari Pharma Inc
Original Assignee
Sitari Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sitari Pharma Inc filed Critical Sitari Pharma Inc
Priority to SM20230186T priority Critical patent/SMT202300186T1/en
Priority to HRP20230798TT priority patent/HRP20230798T1/en
Priority to EP23174889.8A priority patent/EP4219460B1/en
Priority to SI201930559T priority patent/SI3833348T1/en
Priority to RS20230613A priority patent/RS64464B1/en
Publication of EP3833348A1 publication Critical patent/EP3833348A1/en
Publication of EP3833348A4 publication Critical patent/EP3833348A4/en
Application granted granted Critical
Publication of EP3833348B1 publication Critical patent/EP3833348B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
EP19846381.2A 2018-08-10 2019-08-09 Transglutaminase 2 (tg2) inhibitors Active EP3833348B1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SM20230186T SMT202300186T1 (en) 2018-08-10 2019-08-09 Transglutaminase 2 (tg2) inhibitors
HRP20230798TT HRP20230798T1 (en) 2018-08-10 2019-08-09 Transglutaminase 2 (tg2) inhibitors
EP23174889.8A EP4219460B1 (en) 2018-08-10 2019-08-09 Transglutaminase 2 (tg2) inhibitors
SI201930559T SI3833348T1 (en) 2018-08-10 2019-08-09 Transglutaminase 2 (tg2) inhibitors
RS20230613A RS64464B1 (en) 2018-08-10 2019-08-09 Transglutaminase 2 (tg2) inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862717697P 2018-08-10 2018-08-10
US201962845229P 2019-05-08 2019-05-08
PCT/US2019/045827 WO2020033784A1 (en) 2018-08-10 2019-08-09 Transglutaminase 2 (tg2) inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP23174889.8A Division EP4219460B1 (en) 2018-08-10 2019-08-09 Transglutaminase 2 (tg2) inhibitors

Publications (3)

Publication Number Publication Date
EP3833348A1 EP3833348A1 (en) 2021-06-16
EP3833348A4 true EP3833348A4 (en) 2021-06-30
EP3833348B1 EP3833348B1 (en) 2023-05-31

Family

ID=69415167

Family Applications (2)

Application Number Title Priority Date Filing Date
EP19846381.2A Active EP3833348B1 (en) 2018-08-10 2019-08-09 Transglutaminase 2 (tg2) inhibitors
EP23174889.8A Active EP4219460B1 (en) 2018-08-10 2019-08-09 Transglutaminase 2 (tg2) inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP23174889.8A Active EP4219460B1 (en) 2018-08-10 2019-08-09 Transglutaminase 2 (tg2) inhibitors

Country Status (30)

Country Link
US (3) US12152026B2 (en)
EP (2) EP3833348B1 (en)
JP (1) JP7433315B2 (en)
KR (1) KR20210044248A (en)
CN (1) CN112789040A (en)
AU (1) AU2019318543B2 (en)
BR (1) BR112021002532A2 (en)
CA (1) CA3109195A1 (en)
CL (1) CL2021000328A1 (en)
CO (1) CO2021001472A2 (en)
CY (1) CY1126147T1 (en)
DK (1) DK3833348T3 (en)
ES (1) ES2947438T3 (en)
FI (1) FI3833348T3 (en)
HR (1) HRP20230798T1 (en)
HU (1) HUE062140T2 (en)
IL (1) IL280719B2 (en)
LT (1) LT3833348T (en)
MX (1) MX2021001550A (en)
MY (1) MY205622A (en)
PH (1) PH12021500008A1 (en)
PL (1) PL3833348T3 (en)
PT (1) PT3833348T (en)
RS (1) RS64464B1 (en)
SG (1) SG11202100736PA (en)
SI (1) SI3833348T1 (en)
SM (1) SMT202300186T1 (en)
TW (1) TWI825144B (en)
UY (1) UY38333A (en)
WO (1) WO2020033784A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466017B2 (en) 2011-03-10 2022-10-11 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
JP7044375B2 (en) 2016-05-31 2022-03-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Heterocyclic inhibitor of PTPN11
KR102611661B1 (en) 2018-05-02 2023-12-08 나비레 파르마, 인코퍼레이티드 Substituted heterocyclic inhibitor of PTPN11
BR112020024782A2 (en) 2018-06-05 2021-03-02 F. Hoffmann-La Roche Ag tetrahydro-1h-pyrazine [2,1-a] isoindolylquinoline compounds for the treatment of autoimmune disease
SMT202400192T1 (en) 2018-08-10 2024-07-09 Navire Pharma Inc 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
TWI825144B (en) * 2018-08-10 2023-12-11 美商思達利醫藥公司 Transglutaminase 2 (tg2) inhibitors
WO2020227549A1 (en) 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
CN117616011A (en) * 2021-06-30 2024-02-27 策迪拉有限公司 Inhibitors of transglutaminase
AU2022301517A1 (en) * 2021-06-30 2023-12-14 Zedira Gmbh Inhibitors of transglutaminases
US20240300902A1 (en) * 2021-11-18 2024-09-12 Md Biolab Co., Ltd. Novel transglutaminase 2 inhibitor and use thereof
CN115611760A (en) * 2022-10-13 2023-01-17 天津药明康德新药开发有限公司 A chemical synthesis method suitable for large-scale production of (S)-2-amino-5-ynylhexanoic acid
WO2024153137A1 (en) * 2023-01-17 2024-07-25 西藏海思科制药有限公司 Method for preparing chiral amino alcohol pharmaceutical intermediates
CN116891413A (en) * 2023-06-06 2023-10-17 山东东岳高分子材料有限公司 Method for continuously preparing 2,4, 5-trifluoroaniline

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007025247A2 (en) * 2005-08-26 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
WO2012078519A2 (en) * 2010-12-06 2012-06-14 Numerate, Inc. 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
WO2018122419A1 (en) * 2016-12-27 2018-07-05 Zedira Gmbh Inhibitors of transglutaminases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5021440A (en) 1989-07-31 1991-06-04 Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
GB9509271D0 (en) 1995-05-05 1995-06-28 Biopharm Res & Dev Ltd Blood clot stabilisation inhibitors
US20060183759A1 (en) 2004-12-03 2006-08-17 Stein Ross L Tissue transglutaminase inhibitors
DE102006052755A1 (en) 2006-11-08 2008-05-15 N-Zyme Biotec Gmbh New peptide derivatives and peptidomimetics are transglutaminase inhibitors useful for the treatment or prophylaxis of e.g. celiac disease, fibrosis, thrombosis, neurodegenerative disorders, Huntington's chorea and Parkinson disease
EP2558577B1 (en) 2010-04-16 2018-12-12 Nuevolution A/S Bi-functional complexes and methods for making and using such complexes
WO2011151395A2 (en) 2010-06-02 2011-12-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis
US8889716B2 (en) * 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
EP3290413B9 (en) 2011-12-21 2020-04-29 ONO Pharmaceutical Co., Ltd. Pyridinone and pyrimidinone derivatives as factor xia inhibitors
EP2687511A1 (en) * 2012-07-17 2014-01-22 Zedira GmbH Pyridinone derivatives as tissue transglutaminase inhibitors
TW201418198A (en) 2012-09-21 2014-05-16 Chdi Foundation Inc Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
KR101548789B1 (en) 2012-12-21 2015-09-01 주식회사 엘지화학 Cable-type secondary battery and method for manufacturing the same
CN107231804B (en) 2015-01-14 2019-11-26 百时美施贵宝公司 Inferior heteroaryl bridging benzodiazepine * dimer, its conjugate and preparation and application
TWI825144B (en) * 2018-08-10 2023-12-11 美商思達利醫藥公司 Transglutaminase 2 (tg2) inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007025247A2 (en) * 2005-08-26 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
WO2012078519A2 (en) * 2010-12-06 2012-06-14 Numerate, Inc. 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
WO2018122419A1 (en) * 2016-12-27 2018-07-05 Zedira Gmbh Inhibitors of transglutaminases

Also Published As

Publication number Publication date
IL280719B1 (en) 2023-07-01
FI3833348T3 (en) 2023-06-21
WO2020033784A1 (en) 2020-02-13
CL2021000328A1 (en) 2021-08-27
BR112021002532A2 (en) 2021-05-04
CN112789040A (en) 2021-05-11
TW202023553A (en) 2020-07-01
CA3109195A1 (en) 2020-02-13
ES2947438T3 (en) 2023-08-09
LT3833348T (en) 2023-07-10
AU2019318543A1 (en) 2021-03-11
PH12021500008A1 (en) 2021-09-13
IL280719B2 (en) 2023-11-01
EP3833348A1 (en) 2021-06-16
EP4219460A1 (en) 2023-08-02
JP2021534240A (en) 2021-12-09
RS64464B1 (en) 2023-09-29
DK3833348T3 (en) 2023-06-26
IL280719A (en) 2021-03-25
US11548892B1 (en) 2023-01-10
TWI825144B (en) 2023-12-11
MY205622A (en) 2024-10-31
EP3833348B1 (en) 2023-05-31
KR20210044248A (en) 2021-04-22
HRP20230798T1 (en) 2023-10-27
CY1126147T1 (en) 2023-11-15
PT3833348T (en) 2023-06-29
SMT202300186T1 (en) 2023-07-20
CO2021001472A2 (en) 2021-03-08
US20250011324A1 (en) 2025-01-09
AU2019318543B2 (en) 2022-12-22
HUE062140T2 (en) 2023-09-28
US12152026B2 (en) 2024-11-26
SI3833348T1 (en) 2023-08-31
SG11202100736PA (en) 2021-02-25
MX2021001550A (en) 2021-07-15
PL3833348T3 (en) 2023-10-09
UY38333A (en) 2020-05-29
EP4219460B1 (en) 2025-02-26
JP7433315B2 (en) 2024-02-19
US20210163480A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
EP3833348A4 (en) TRANSGLUTAMINASE 2 (TG2) INHIBITORS
MA54543A (en) KIF18A INHIBITORS
MA54550A (en) KIF18A INHIBITORS
MA51616A (en) DNA-PK INHIBITORS
HUE062096T2 (en) Pyridazinones as PARP7 inhibitors
EP3844870A4 (en) ASSET TRACKER
MA52413A (en) CD73 INHIBITORS
MA53287A (en) PRMT5 INHIBITORS
MA52812A (en) SARM1 INHIBITORS
MA52004A (en) O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS
EP3817736A4 (en) PIKFYVE INHIBITORS
EP3766984A4 (en) DETERMINATION PROCEDURE
EP3801500A4 (en) MRSA1 INHIBITORS
MA52809A (en) SARM1 INHIBITORS
EP3786157A4 (en) PHENYLTRIAZOL-MLL1-WDR5-PROTEIN-PROTEIN-INTERACTION INHIBITOR
DK3946179T3 (en) STOMY POSES
EP3833669A4 (en) PRMT5 INHIBITORS
EP3769829A4 (en) BLOCK ELEMENT SET
EP3999517A4 (en) CD73 INHIBITORS
EP4051688A4 (en) CD73 INHIBITORS
PT3980417T (en) PRMT5 INHIBITORS
EP3919491A4 (en) ACT INHIBITOR
MA49006A (en) IP6K INHIBITORS
EP3897152C0 (en) NEMATICIDAL COMPOSITIONS
MA51611A (en) PI4KIIIBETA INHIBITORS

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20230798T

Country of ref document: HR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602019029633

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0031441200

Ipc: C07D0401060000

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17P Request for examination filed

Effective date: 20210226

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

A4 Supplementary search report drawn up and despatched

Effective date: 20210528

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 401/06 20060101AFI20210521BHEP

Ipc: C07D 401/14 20060101ALI20210521BHEP

Ipc: C07D 403/02 20060101ALI20210521BHEP

Ipc: C07D 403/06 20060101ALI20210521BHEP

Ipc: C07D 405/14 20060101ALI20210521BHEP

Ipc: C07D 413/06 20060101ALI20210521BHEP

Ipc: C07D 413/14 20060101ALI20210521BHEP

Ipc: C07D 417/06 20060101ALI20210521BHEP

Ipc: C07D 417/14 20060101ALI20210521BHEP

Ipc: C07D 471/04 20060101ALI20210521BHEP

Ipc: C07D 473/00 20060101ALI20210521BHEP

Ipc: C07D 473/30 20060101ALI20210521BHEP

Ipc: C07D 473/34 20060101ALI20210521BHEP

Ipc: A61K 31/4412 20060101ALI20210521BHEP

Ipc: A61K 38/05 20060101ALI20210521BHEP

Ipc: A61P 25/00 20060101ALI20210521BHEP

Ipc: A61P 35/00 20060101ALI20210521BHEP

Ipc: A61P 43/00 20060101ALI20210521BHEP

17Q First examination report despatched

Effective date: 20210610

RAV Requested validation state of the european patent: fee paid

Extension state: MA

Effective date: 20210226

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40052686

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220214

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20220708

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SITARI PHARMA, INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DURON, SERGIO, G.

Inventor name: DIRAIMONDO, THOMAS, R.

Inventor name: CHEUNG, MUI, H.

Inventor name: CHAPMAN, JUSTIN

Inventor name: CAMPBELL, DAVID

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20221216

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602019029633

Country of ref document: DE

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230331

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1570875

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230615

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20230619

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3833348

Country of ref document: PT

Date of ref document: 20230629

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20230623

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2947438

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20230809

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 41831

Country of ref document: SK

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20230531

REG Reference to a national code

Ref country code: MA

Ref legal event code: VAGR

Ref document number: 53285

Country of ref document: MA

Kind code of ref document: B1

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E062140

Country of ref document: HU

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20230798T

Country of ref document: HR

Payment date: 20230727

Year of fee payment: 5

Ref country code: GR

Ref legal event code: EP

Ref document number: 20230401067

Country of ref document: GR

Effective date: 20230908

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E023475

Country of ref document: EE

Effective date: 20230801

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20230798

Country of ref document: HR

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20230721

Year of fee payment: 5

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602019029633

Country of ref document: DE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20230724

Year of fee payment: 5

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20240301

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20240723

Year of fee payment: 6

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20230798

Country of ref document: HR

Payment date: 20240729

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240723

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20240723

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20240725

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20240724

Year of fee payment: 6

Ref country code: LT

Payment date: 20240723

Year of fee payment: 6

Ref country code: HR

Payment date: 20240729

Year of fee payment: 6

Ref country code: IE

Payment date: 20240725

Year of fee payment: 6

Ref country code: DE

Payment date: 20240723

Year of fee payment: 6

Ref country code: MC

Payment date: 20240729

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240725

Year of fee payment: 6

Ref country code: DK

Payment date: 20240723

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240723

Year of fee payment: 6

Ref country code: SM

Payment date: 20240724

Year of fee payment: 6

Ref country code: PT

Payment date: 20240725

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20240723

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240723

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240902

Year of fee payment: 6

Ref country code: CH

Payment date: 20240901

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20240725

Year of fee payment: 6

Ref country code: EE

Payment date: 20240723

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240725

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20240726

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20240726

Year of fee payment: 6

Ref country code: HU

Payment date: 20240813

Year of fee payment: 6

Ref country code: SI

Payment date: 20240731

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LV

Payment date: 20240723

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20240809

Year of fee payment: 6

Ref country code: NO

Payment date: 20240725

Year of fee payment: 6

Ref country code: IT

Payment date: 20240723

Year of fee payment: 6

Ref country code: RS

Payment date: 20240729

Year of fee payment: 6

Ref country code: SE

Payment date: 20240723

Year of fee payment: 6

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1570875

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230531

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20240730

Year of fee payment: 6

Ref country code: MT

Payment date: 20240808

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20240822

Year of fee payment: 6